系统性长期药物对与年龄相关的黄斑变性发展的影响
Hanna Heloterä1, Reijo Sund2, Toni Rikkonen3
1Department of Ophthalmology, University of Eastern Finland, Kuopio, Finland.
Acta ophthalmologica
|March 6, 2026
概括
长期使用全身皮质类固醇和免疫抑制剂会增加患年龄相关黄斑变性 (AMD) 的风险. 需要进一步的研究,以了解影响这些患者AMD进展的系统因素.
科学领域:
- 眼科医生 眼科 眼科
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是老年人视力丧失的主要原因.
- 影响AMD发病率和进展的系统因素尚未完全理解.
研究的目的:
- 研究长期使用全身药物和AMD发展之间的关联.
- 具体检查糖尿病,抗血栓,皮质类固醇和免疫抑制药物.
主要方法:
- 两项后续研究 (Kuopio骨质疏松风险因素和预防研究和Kuopio落预防研究) 的综合分析.
- 包括16,518名妇女 (出生于1932年至1946年) 在芬兰东部,跟踪从1993年至2021年.
- 长期使用药物定义为≥5年定期购买药物.
主要成果:
- 长期使用全身皮质类固醇 (HR 1.348) 和免疫抑制剂 (HR 1.623) 观察到AMD的几率增加.
- 抗血栓药物使用显示增加了几率 (HR 1.145),但结果不太一致.
- 在AMD诊断时的平均年龄在抗血栓使用者 (77.9岁) 与对照者 (76.1岁) 之间较晚,而在非甲胺糖尿病药物使用者 (75.3岁) 与对照者 (77.1岁) 之间较早.
结论:
- 长期使用皮质类固醇和免疫抑制剂与患AMD的风险增加有关.
- 需要进一步的研究来探索可能调节AMD进展的与这些药物相关的全身因素.
更多相关视频
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
771
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
771
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
283
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
283
Pharmacodynamics in Geriatric Patients: Effects of Age
294
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
294
Drug Dosing: Geriatric Patients
334
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
334
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
294
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
294
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
306
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
306


